Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Research output: Contribution to journalArticle

Authors

  • Paul Milne
  • Charlotte Wilhelm-Benartzi
  • Michael R Grunwald
  • Venetia Bigley
  • Richard Dillon
  • Kathleen Gallagher
  • Amy Publicover
  • Sarah Pagan
  • Helen Marr
  • Gail L Jones
  • Anne M Dickinson
  • Angela Grech
  • Alan K Burnett
  • Nigel H Russell
  • Mark Levis
  • Steven Knapper
  • Matthew Collin

Colleges, School and Institutes

External organisations

  • NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom.
  • Cardiff University
  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • King's College London
  • Immune Monitoring Laboratory, Massachusetts General Hospital Center for Cancer Research, Boston, MA.
  • Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
  • Department of Haematology, Nottingham University Hospital, Nottingham, United Kingdom; and.
  • Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD.

Abstract

Fms-like tyrosine kinase 3 (Flt3) is expressed on progenitor cells and acute myeloid leukemia (AML) blasts. Fms-like tyrosine kinase 3 ligand (Flt3L) is detectable during homeostasis and increases in hypoplasia due to genetic defects or treatment with cytoreductive agents. Conversely, Flt3+ AML is associated with depletion of Flt3L to undetectable levels. After induction chemotherapy, Flt3L is restored in patients entering complete remission (CR) but remains depressed in those with refractory disease. Weekly sampling reveals marked differences in the kinetics of Flt3L response during the first 6 weeks of treatment, proportionate to the clearance of blasts and cellularity of the bone marrow. In the UK NCRI AML17 trial, Flt3L was measured at day 26 in a subgroup of 140 patients with Flt3 mutation randomized to the tyrosine kinase inhibitor lestaurtinib or placebo. In these patients, attainment of CR was associated with higher Flt3L at day 26 (Mann-Whitney UP < .0001). Day 26 Flt3L was also associated with survival; Flt3L ≤291 pg/mL was associated with inferior event-free survival (EFS), and Flt3L >1185 pg/mL was associated with higher overall survival (OS; P = .0119). The separation of EFS and OS curves increased when minimal residual disease (MRD) status was combined with Flt3L measurement, and Flt3L retained a near-significant association with survival after adjusting for MRD in a proportional hazards model. Serial measurement of Flt3L in patients who had received a hematopoietic stem cell transplant for AML illustrates the potential value of monitoring Flt3L to identify relapse. Measurement of Flt3L is a noninvasive test with the potential to inform clinical decisions in patients with AML.

Bibliographic note

© 2019 by The American Society of Hematology.

Details

Original languageEnglish
Pages (from-to)3052-3061
Number of pages10
JournalBlood Advances
Volume3
Issue number20
Publication statusPublished - 22 Oct 2019

Keywords

  • flt3 ligand, stem cells, leukemia, myelocytic, acute